nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—migraine—Prednisone—prostate cancer	0.294	1	CpDpCtD
Eletriptan—CYP2A6—prostate cancer	0.108	0.465	CbGaD
Eletriptan—CYP2C19—prostate cancer	0.0757	0.327	CbGaD
Eletriptan—CYP3A4—prostate cancer	0.0481	0.208	CbGaD
Eletriptan—CYP2C19—Bicalutamide—prostate cancer	0.0166	0.0607	CbGbCtD
Eletriptan—CYP2C19—Nilutamide—prostate cancer	0.0166	0.0607	CbGbCtD
Eletriptan—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0153	0.0559	CbGbCtD
Eletriptan—CYP2C9—Bicalutamide—prostate cancer	0.0138	0.0505	CbGbCtD
Eletriptan—CYP2C9—Nilutamide—prostate cancer	0.0138	0.0505	CbGbCtD
Eletriptan—CYP2C19—Flutamide—prostate cancer	0.0138	0.0503	CbGbCtD
Eletriptan—CYP2D6—Bicalutamide—prostate cancer	0.0126	0.0462	CbGbCtD
Eletriptan—ABCB1—Estramustine—prostate cancer	0.0125	0.0456	CbGbCtD
Eletriptan—CYP2D6—Abiraterone—prostate cancer	0.0105	0.0383	CbGbCtD
Eletriptan—CYP2C9—Estrone—prostate cancer	0.00827	0.0303	CbGbCtD
Eletriptan—ABCB1—Cabazitaxel—prostate cancer	0.00821	0.03	CbGbCtD
Eletriptan—CYP3A4—Bicalutamide—prostate cancer	0.00803	0.0294	CbGbCtD
Eletriptan—ABCB1—Estrone—prostate cancer	0.00803	0.0294	CbGbCtD
Eletriptan—PTGS1—Etoposide—prostate cancer	0.00771	0.0282	CbGbCtD
Eletriptan—CYP3A4—Estramustine—prostate cancer	0.00747	0.0273	CbGbCtD
Eletriptan—ABCB1—Ethinyl Estradiol—prostate cancer	0.00716	0.0262	CbGbCtD
Eletriptan—CYP3A4—Abiraterone—prostate cancer	0.00665	0.0243	CbGbCtD
Eletriptan—CYP3A4—Flutamide—prostate cancer	0.00665	0.0243	CbGbCtD
Eletriptan—CYP2C9—Capecitabine—prostate cancer	0.00627	0.0229	CbGbCtD
Eletriptan—HTR7—vas deferens—prostate cancer	0.00584	0.362	CbGeAlD
Eletriptan—CYP2C19—Estradiol—prostate cancer	0.00572	0.0209	CbGbCtD
Eletriptan—ABCB1—Conjugated Estrogens—prostate cancer	0.00525	0.0192	CbGbCtD
Eletriptan—CYP3A4—Cabazitaxel—prostate cancer	0.00492	0.018	CbGbCtD
Eletriptan—CYP2C19—Prednisone—prostate cancer	0.00491	0.018	CbGbCtD
Eletriptan—CYP3A4—Estrone—prostate cancer	0.00481	0.0176	CbGbCtD
Eletriptan—ABCB1—Mitoxantrone—prostate cancer	0.00477	0.0175	CbGbCtD
Eletriptan—CYP2C9—Estradiol—prostate cancer	0.00475	0.0174	CbGbCtD
Eletriptan—ABCB1—Estradiol—prostate cancer	0.00461	0.0169	CbGbCtD
Eletriptan—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00429	0.0157	CbGbCtD
Eletriptan—ABCB1—Prednisone—prostate cancer	0.00397	0.0145	CbGbCtD
Eletriptan—CYP3A4—Conjugated Estrogens—prostate cancer	0.00315	0.0115	CbGbCtD
Eletriptan—ABCB1—Etoposide—prostate cancer	0.00301	0.011	CbGbCtD
Eletriptan—CYP3A4—Mitoxantrone—prostate cancer	0.00286	0.0105	CbGbCtD
Eletriptan—CYP3A4—Estradiol—prostate cancer	0.00276	0.0101	CbGbCtD
Eletriptan—ABCB1—Docetaxel—prostate cancer	0.00275	0.0101	CbGbCtD
Eletriptan—CYP3A4—Prednisone—prostate cancer	0.00238	0.00869	CbGbCtD
Eletriptan—ABCB1—Doxorubicin—prostate cancer	0.00205	0.00751	CbGbCtD
Eletriptan—CYP2D6—Doxorubicin—prostate cancer	0.00194	0.00708	CbGbCtD
Eletriptan—CYP3A4—Etoposide—prostate cancer	0.0018	0.0066	CbGbCtD
Eletriptan—CYP3A4—Docetaxel—prostate cancer	0.00165	0.00604	CbGbCtD
Eletriptan—CYP2C19—urine—prostate cancer	0.00142	0.088	CbGeAlD
Eletriptan—CYP3A4—Doxorubicin—prostate cancer	0.00123	0.0045	CbGbCtD
Eletriptan—CYP2C9—urine—prostate cancer	0.0011	0.0683	CbGeAlD
Eletriptan—CYP3A4—urine—prostate cancer	0.000839	0.052	CbGeAlD
Eletriptan—CYP2D6—urine—prostate cancer	0.000826	0.0512	CbGeAlD
Eletriptan—CYP2A6—prostate gland—prostate cancer	0.000792	0.0491	CbGeAlD
Eletriptan—CYP2A6—seminal vesicle—prostate cancer	0.00067	0.0416	CbGeAlD
Eletriptan—HTR7—epithelium—prostate cancer	0.000383	0.0238	CbGeAlD
Eletriptan—HTR1A—renal system—prostate cancer	0.000372	0.0231	CbGeAlD
Eletriptan—PTGS1—prostate gland—prostate cancer	0.000361	0.0224	CbGeAlD
Eletriptan—HTR7—renal system—prostate cancer	0.000356	0.0221	CbGeAlD
Eletriptan—PTGS1—seminal vesicle—prostate cancer	0.000305	0.0189	CbGeAlD
Eletriptan—PTGS1—epithelium—prostate cancer	0.000265	0.0164	CbGeAlD
Eletriptan—PTGS1—renal system—prostate cancer	0.000246	0.0152	CbGeAlD
Eletriptan—HTR7—testis—prostate cancer	0.00023	0.0143	CbGeAlD
Eletriptan—ABCB1—prostate gland—prostate cancer	0.000213	0.0132	CbGeAlD
Eletriptan—CYP3A4—renal system—prostate cancer	0.000205	0.0127	CbGeAlD
Eletriptan—CYP2D6—renal system—prostate cancer	0.000202	0.0125	CbGeAlD
Eletriptan—HTR2B—lymph node—prostate cancer	0.000195	0.0121	CbGeAlD
Eletriptan—ABCB1—seminal vesicle—prostate cancer	0.00018	0.0112	CbGeAlD
Eletriptan—Almotriptan—CYP2E1—prostate cancer	0.000168	0.242	CrCbGaD
Eletriptan—Almotriptan—CYP2C19—prostate cancer	0.000166	0.24	CrCbGaD
Eletriptan—PTGS1—testis—prostate cancer	0.000159	0.00985	CbGeAlD
Eletriptan—ABCB1—epithelium—prostate cancer	0.000157	0.00972	CbGeAlD
Eletriptan—ABCB1—renal system—prostate cancer	0.000145	0.00901	CbGeAlD
Eletriptan—ABCB1—urethra—prostate cancer	0.000143	0.00885	CbGeAlD
Eletriptan—CYP2D6—testis—prostate cancer	0.000131	0.0081	CbGeAlD
Eletriptan—Clemastine—CYP3A4—prostate cancer	0.000122	0.176	CrCbGaD
Eletriptan—PTGS1—lymph node—prostate cancer	0.000115	0.00714	CbGeAlD
Eletriptan—ABCB1—bone marrow—prostate cancer	0.00011	0.00682	CbGeAlD
Eletriptan—Almotriptan—CYP3A4—prostate cancer	0.000106	0.153	CrCbGaD
Eletriptan—ABCB1—testis—prostate cancer	9.4e-05	0.00583	CbGeAlD
Eletriptan—ABCB1—lymph node—prostate cancer	6.81e-05	0.00422	CbGeAlD
Eletriptan—Thioridazine—CYP2E1—prostate cancer	6.57e-05	0.0948	CrCbGaD
Eletriptan—Thioridazine—CYP2C19—prostate cancer	6.51e-05	0.0939	CrCbGaD
Eletriptan—Hyperhidrosis—Capecitabine—prostate cancer	2.35e-05	0.0002	CcSEcCtD
Eletriptan—Oedema peripheral—Epirubicin—prostate cancer	2.35e-05	0.0002	CcSEcCtD
Eletriptan—Hypotension—Docetaxel—prostate cancer	2.35e-05	0.000199	CcSEcCtD
Eletriptan—Urethral disorder—Epirubicin—prostate cancer	2.34e-05	0.000199	CcSEcCtD
Eletriptan—Loss of consciousness—Prednisone—prostate cancer	2.34e-05	0.000198	CcSEcCtD
Eletriptan—Epistaxis—Doxorubicin—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Eletriptan—Anorexia—Capecitabine—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Eletriptan—Nausea—Estradiol—prostate cancer	2.32e-05	0.000197	CcSEcCtD
Eletriptan—Vomiting—Mitoxantrone—prostate cancer	2.31e-05	0.000196	CcSEcCtD
Eletriptan—Sinusitis—Doxorubicin—prostate cancer	2.31e-05	0.000196	CcSEcCtD
Eletriptan—Convulsion—Prednisone—prostate cancer	2.3e-05	0.000195	CcSEcCtD
Eletriptan—Visual impairment—Epirubicin—prostate cancer	2.3e-05	0.000195	CcSEcCtD
Eletriptan—Hypertension—Prednisone—prostate cancer	2.29e-05	0.000195	CcSEcCtD
Eletriptan—Rash—Mitoxantrone—prostate cancer	2.29e-05	0.000195	CcSEcCtD
Eletriptan—Dermatitis—Mitoxantrone—prostate cancer	2.29e-05	0.000195	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.29e-05	0.000194	CcSEcCtD
Eletriptan—Headache—Mitoxantrone—prostate cancer	2.28e-05	0.000193	CcSEcCtD
Eletriptan—Hypotension—Capecitabine—prostate cancer	2.27e-05	0.000193	CcSEcCtD
Eletriptan—Insomnia—Docetaxel—prostate cancer	2.27e-05	0.000193	CcSEcCtD
Eletriptan—Myalgia—Prednisone—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Eletriptan—Arthralgia—Prednisone—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Eletriptan—Paraesthesia—Docetaxel—prostate cancer	2.26e-05	0.000192	CcSEcCtD
Eletriptan—Anxiety—Prednisone—prostate cancer	2.25e-05	0.000191	CcSEcCtD
Eletriptan—Bradycardia—Doxorubicin—prostate cancer	2.25e-05	0.000191	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.25e-05	0.000191	CcSEcCtD
Eletriptan—Dyspnoea—Docetaxel—prostate cancer	2.24e-05	0.00019	CcSEcCtD
Eletriptan—Somnolence—Docetaxel—prostate cancer	2.24e-05	0.00019	CcSEcCtD
Eletriptan—Discomfort—Prednisone—prostate cancer	2.23e-05	0.00019	CcSEcCtD
Eletriptan—Hypersensitivity—Etoposide—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Eletriptan—Tinnitus—Epirubicin—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.22e-05	0.000188	CcSEcCtD
Eletriptan—Flushing—Epirubicin—prostate cancer	2.22e-05	0.000188	CcSEcCtD
Eletriptan—Rhinitis—Doxorubicin—prostate cancer	2.21e-05	0.000188	CcSEcCtD
Eletriptan—Dyspepsia—Docetaxel—prostate cancer	2.21e-05	0.000188	CcSEcCtD
Eletriptan—Insomnia—Capecitabine—prostate cancer	2.2e-05	0.000187	CcSEcCtD
Eletriptan—Hypoaesthesia—Doxorubicin—prostate cancer	2.2e-05	0.000187	CcSEcCtD
Eletriptan—Pharyngitis—Doxorubicin—prostate cancer	2.19e-05	0.000186	CcSEcCtD
Eletriptan—Paraesthesia—Capecitabine—prostate cancer	2.19e-05	0.000186	CcSEcCtD
Eletriptan—Decreased appetite—Docetaxel—prostate cancer	2.19e-05	0.000186	CcSEcCtD
Eletriptan—Urinary tract disorder—Doxorubicin—prostate cancer	2.18e-05	0.000185	CcSEcCtD
Eletriptan—Oedema peripheral—Doxorubicin—prostate cancer	2.18e-05	0.000185	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Docetaxel—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Eletriptan—Asthenia—Etoposide—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Eletriptan—Dyspnoea—Capecitabine—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Eletriptan—Oedema—Prednisone—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Eletriptan—Fatigue—Docetaxel—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Eletriptan—Urethral disorder—Doxorubicin—prostate cancer	2.16e-05	0.000184	CcSEcCtD
Eletriptan—Nausea—Mitoxantrone—prostate cancer	2.16e-05	0.000183	CcSEcCtD
Eletriptan—Immune system disorder—Epirubicin—prostate cancer	2.16e-05	0.000183	CcSEcCtD
Eletriptan—Pain—Docetaxel—prostate cancer	2.15e-05	0.000183	CcSEcCtD
Eletriptan—Constipation—Docetaxel—prostate cancer	2.15e-05	0.000183	CcSEcCtD
Eletriptan—Dyspepsia—Capecitabine—prostate cancer	2.14e-05	0.000182	CcSEcCtD
Eletriptan—Chills—Epirubicin—prostate cancer	2.14e-05	0.000182	CcSEcCtD
Eletriptan—Pruritus—Etoposide—prostate cancer	2.14e-05	0.000182	CcSEcCtD
Eletriptan—Shock—Prednisone—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Eletriptan—Arrhythmia—Epirubicin—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Eletriptan—Visual impairment—Doxorubicin—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Eletriptan—Nervous system disorder—Prednisone—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Eletriptan—Tachycardia—Prednisone—prostate cancer	2.12e-05	0.00018	CcSEcCtD
Eletriptan—Decreased appetite—Capecitabine—prostate cancer	2.12e-05	0.00018	CcSEcCtD
Eletriptan—Alopecia—Epirubicin—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Eletriptan—Skin disorder—Prednisone—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Capecitabine—prostate cancer	2.1e-05	0.000178	CcSEcCtD
Eletriptan—Fatigue—Capecitabine—prostate cancer	2.1e-05	0.000178	CcSEcCtD
Eletriptan—Hyperhidrosis—Prednisone—prostate cancer	2.1e-05	0.000178	CcSEcCtD
Eletriptan—Pain—Capecitabine—prostate cancer	2.08e-05	0.000177	CcSEcCtD
Eletriptan—Constipation—Capecitabine—prostate cancer	2.08e-05	0.000177	CcSEcCtD
Eletriptan—Feeling abnormal—Docetaxel—prostate cancer	2.07e-05	0.000176	CcSEcCtD
Eletriptan—Diarrhoea—Etoposide—prostate cancer	2.07e-05	0.000176	CcSEcCtD
Eletriptan—Anorexia—Prednisone—prostate cancer	2.07e-05	0.000175	CcSEcCtD
Eletriptan—Tinnitus—Doxorubicin—prostate cancer	2.06e-05	0.000175	CcSEcCtD
Eletriptan—Gastrointestinal pain—Docetaxel—prostate cancer	2.06e-05	0.000175	CcSEcCtD
Eletriptan—Flushing—Doxorubicin—prostate cancer	2.05e-05	0.000174	CcSEcCtD
Eletriptan—Flatulence—Epirubicin—prostate cancer	2.05e-05	0.000174	CcSEcCtD
Eletriptan—Tension—Epirubicin—prostate cancer	2.04e-05	0.000173	CcSEcCtD
Eletriptan—Dysgeusia—Epirubicin—prostate cancer	2.03e-05	0.000173	CcSEcCtD
Eletriptan—Nervousness—Epirubicin—prostate cancer	2.02e-05	0.000171	CcSEcCtD
Eletriptan—Back pain—Epirubicin—prostate cancer	2.01e-05	0.000171	CcSEcCtD
Eletriptan—Feeling abnormal—Capecitabine—prostate cancer	2.01e-05	0.00017	CcSEcCtD
Eletriptan—Dizziness—Etoposide—prostate cancer	2e-05	0.00017	CcSEcCtD
Eletriptan—Muscle spasms—Epirubicin—prostate cancer	2e-05	0.00017	CcSEcCtD
Eletriptan—Immune system disorder—Doxorubicin—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Eletriptan—Gastrointestinal pain—Capecitabine—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Eletriptan—Abdominal pain—Docetaxel—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Eletriptan—Body temperature increased—Docetaxel—prostate cancer	1.99e-05	0.000169	CcSEcCtD
Eletriptan—Chills—Doxorubicin—prostate cancer	1.98e-05	0.000168	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Prednisone—prostate cancer	1.98e-05	0.000168	CcSEcCtD
Eletriptan—Arrhythmia—Doxorubicin—prostate cancer	1.97e-05	0.000168	CcSEcCtD
Eletriptan—Insomnia—Prednisone—prostate cancer	1.96e-05	0.000166	CcSEcCtD
Eletriptan—Alopecia—Doxorubicin—prostate cancer	1.95e-05	0.000166	CcSEcCtD
Eletriptan—Paraesthesia—Prednisone—prostate cancer	1.95e-05	0.000165	CcSEcCtD
Eletriptan—Urticaria—Capecitabine—prostate cancer	1.93e-05	0.000164	CcSEcCtD
Eletriptan—Ill-defined disorder—Epirubicin—prostate cancer	1.93e-05	0.000164	CcSEcCtD
Eletriptan—Abdominal pain—Capecitabine—prostate cancer	1.92e-05	0.000163	CcSEcCtD
Eletriptan—Body temperature increased—Capecitabine—prostate cancer	1.92e-05	0.000163	CcSEcCtD
Eletriptan—Vomiting—Etoposide—prostate cancer	1.92e-05	0.000163	CcSEcCtD
Eletriptan—Anaemia—Epirubicin—prostate cancer	1.92e-05	0.000163	CcSEcCtD
Eletriptan—Agitation—Epirubicin—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Eletriptan—Dyspepsia—Prednisone—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Eletriptan—Rash—Etoposide—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Eletriptan—Dermatitis—Etoposide—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Eletriptan—Headache—Etoposide—prostate cancer	1.9e-05	0.000161	CcSEcCtD
Eletriptan—Flatulence—Doxorubicin—prostate cancer	1.89e-05	0.000161	CcSEcCtD
Eletriptan—Tension—Doxorubicin—prostate cancer	1.89e-05	0.00016	CcSEcCtD
Eletriptan—Decreased appetite—Prednisone—prostate cancer	1.88e-05	0.00016	CcSEcCtD
Eletriptan—Dysgeusia—Doxorubicin—prostate cancer	1.88e-05	0.00016	CcSEcCtD
Eletriptan—Malaise—Epirubicin—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Eletriptan—Fatigue—Prednisone—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Eletriptan—Nervousness—Doxorubicin—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Eletriptan—Vertigo—Epirubicin—prostate cancer	1.87e-05	0.000158	CcSEcCtD
Eletriptan—Syncope—Epirubicin—prostate cancer	1.86e-05	0.000158	CcSEcCtD
Eletriptan—Leukopenia—Epirubicin—prostate cancer	1.86e-05	0.000158	CcSEcCtD
Eletriptan—Back pain—Doxorubicin—prostate cancer	1.86e-05	0.000158	CcSEcCtD
Eletriptan—Constipation—Prednisone—prostate cancer	1.85e-05	0.000157	CcSEcCtD
Eletriptan—Hypersensitivity—Docetaxel—prostate cancer	1.85e-05	0.000157	CcSEcCtD
Eletriptan—Muscle spasms—Doxorubicin—prostate cancer	1.85e-05	0.000157	CcSEcCtD
Eletriptan—Palpitations—Epirubicin—prostate cancer	1.84e-05	0.000156	CcSEcCtD
Eletriptan—Loss of consciousness—Epirubicin—prostate cancer	1.83e-05	0.000155	CcSEcCtD
Eletriptan—Cough—Epirubicin—prostate cancer	1.81e-05	0.000154	CcSEcCtD
Eletriptan—Asthenia—Docetaxel—prostate cancer	1.8e-05	0.000153	CcSEcCtD
Eletriptan—Convulsion—Epirubicin—prostate cancer	1.8e-05	0.000153	CcSEcCtD
Eletriptan—Nausea—Etoposide—prostate cancer	1.8e-05	0.000153	CcSEcCtD
Eletriptan—Hypertension—Epirubicin—prostate cancer	1.79e-05	0.000152	CcSEcCtD
Eletriptan—Hypersensitivity—Capecitabine—prostate cancer	1.79e-05	0.000152	CcSEcCtD
Eletriptan—Feeling abnormal—Prednisone—prostate cancer	1.79e-05	0.000152	CcSEcCtD
Eletriptan—Ill-defined disorder—Doxorubicin—prostate cancer	1.78e-05	0.000151	CcSEcCtD
Eletriptan—Pruritus—Docetaxel—prostate cancer	1.78e-05	0.000151	CcSEcCtD
Eletriptan—Anaemia—Doxorubicin—prostate cancer	1.78e-05	0.000151	CcSEcCtD
Eletriptan—Gastrointestinal pain—Prednisone—prostate cancer	1.77e-05	0.000151	CcSEcCtD
Eletriptan—Arthralgia—Epirubicin—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Eletriptan—Myalgia—Epirubicin—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Eletriptan—Agitation—Doxorubicin—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Eletriptan—Anxiety—Epirubicin—prostate cancer	1.76e-05	0.00015	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.76e-05	0.000149	CcSEcCtD
Eletriptan—Discomfort—Epirubicin—prostate cancer	1.75e-05	0.000148	CcSEcCtD
Eletriptan—Asthenia—Capecitabine—prostate cancer	1.75e-05	0.000148	CcSEcCtD
Eletriptan—Malaise—Doxorubicin—prostate cancer	1.73e-05	0.000147	CcSEcCtD
Eletriptan—Dry mouth—Epirubicin—prostate cancer	1.73e-05	0.000147	CcSEcCtD
Eletriptan—Vertigo—Doxorubicin—prostate cancer	1.73e-05	0.000147	CcSEcCtD
Eletriptan—Syncope—Doxorubicin—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Eletriptan—Urticaria—Prednisone—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Eletriptan—Pruritus—Capecitabine—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Eletriptan—Leukopenia—Doxorubicin—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Eletriptan—Diarrhoea—Docetaxel—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Eletriptan—Body temperature increased—Prednisone—prostate cancer	1.71e-05	0.000146	CcSEcCtD
Eletriptan—Abdominal pain—Prednisone—prostate cancer	1.71e-05	0.000146	CcSEcCtD
Eletriptan—Confusional state—Epirubicin—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Eletriptan—Palpitations—Doxorubicin—prostate cancer	1.7e-05	0.000144	CcSEcCtD
Eletriptan—Oedema—Epirubicin—prostate cancer	1.7e-05	0.000144	CcSEcCtD
Eletriptan—Loss of consciousness—Doxorubicin—prostate cancer	1.69e-05	0.000143	CcSEcCtD
Eletriptan—Cough—Doxorubicin—prostate cancer	1.68e-05	0.000142	CcSEcCtD
Eletriptan—Shock—Epirubicin—prostate cancer	1.67e-05	0.000142	CcSEcCtD
Eletriptan—Convulsion—Doxorubicin—prostate cancer	1.67e-05	0.000141	CcSEcCtD
Eletriptan—Diarrhoea—Capecitabine—prostate cancer	1.67e-05	0.000141	CcSEcCtD
Eletriptan—Nervous system disorder—Epirubicin—prostate cancer	1.66e-05	0.000141	CcSEcCtD
Eletriptan—Dizziness—Docetaxel—prostate cancer	1.66e-05	0.000141	CcSEcCtD
Eletriptan—Hypertension—Doxorubicin—prostate cancer	1.66e-05	0.000141	CcSEcCtD
Eletriptan—Tachycardia—Epirubicin—prostate cancer	1.66e-05	0.000141	CcSEcCtD
Eletriptan—Skin disorder—Epirubicin—prostate cancer	1.65e-05	0.00014	CcSEcCtD
Eletriptan—Hyperhidrosis—Epirubicin—prostate cancer	1.64e-05	0.000139	CcSEcCtD
Eletriptan—Myalgia—Doxorubicin—prostate cancer	1.64e-05	0.000139	CcSEcCtD
Eletriptan—Arthralgia—Doxorubicin—prostate cancer	1.64e-05	0.000139	CcSEcCtD
Eletriptan—Anxiety—Doxorubicin—prostate cancer	1.63e-05	0.000138	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.63e-05	0.000138	CcSEcCtD
Eletriptan—Discomfort—Doxorubicin—prostate cancer	1.62e-05	0.000137	CcSEcCtD
Eletriptan—Anorexia—Epirubicin—prostate cancer	1.62e-05	0.000137	CcSEcCtD
Eletriptan—Dizziness—Capecitabine—prostate cancer	1.61e-05	0.000137	CcSEcCtD
Eletriptan—Dry mouth—Doxorubicin—prostate cancer	1.6e-05	0.000136	CcSEcCtD
Eletriptan—Vomiting—Docetaxel—prostate cancer	1.6e-05	0.000136	CcSEcCtD
Eletriptan—Hypersensitivity—Prednisone—prostate cancer	1.6e-05	0.000136	CcSEcCtD
Eletriptan—Rash—Docetaxel—prostate cancer	1.59e-05	0.000135	CcSEcCtD
Eletriptan—Hypotension—Epirubicin—prostate cancer	1.58e-05	0.000135	CcSEcCtD
Eletriptan—Dermatitis—Docetaxel—prostate cancer	1.58e-05	0.000134	CcSEcCtD
Eletriptan—Confusional state—Doxorubicin—prostate cancer	1.58e-05	0.000134	CcSEcCtD
Eletriptan—Headache—Docetaxel—prostate cancer	1.58e-05	0.000134	CcSEcCtD
Eletriptan—Oedema—Doxorubicin—prostate cancer	1.57e-05	0.000133	CcSEcCtD
Eletriptan—Asthenia—Prednisone—prostate cancer	1.56e-05	0.000132	CcSEcCtD
Eletriptan—Vomiting—Capecitabine—prostate cancer	1.55e-05	0.000131	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.55e-05	0.000131	CcSEcCtD
Eletriptan—Shock—Doxorubicin—prostate cancer	1.54e-05	0.000131	CcSEcCtD
Eletriptan—Nervous system disorder—Doxorubicin—prostate cancer	1.54e-05	0.000131	CcSEcCtD
Eletriptan—Rash—Capecitabine—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Eletriptan—Pruritus—Prednisone—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Eletriptan—Insomnia—Epirubicin—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Eletriptan—Dermatitis—Capecitabine—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Eletriptan—Tachycardia—Doxorubicin—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Eletriptan—Headache—Capecitabine—prostate cancer	1.52e-05	0.000129	CcSEcCtD
Eletriptan—Skin disorder—Doxorubicin—prostate cancer	1.52e-05	0.000129	CcSEcCtD
Eletriptan—Paraesthesia—Epirubicin—prostate cancer	1.52e-05	0.000129	CcSEcCtD
Eletriptan—Hyperhidrosis—Doxorubicin—prostate cancer	1.52e-05	0.000129	CcSEcCtD
Eletriptan—Dyspnoea—Epirubicin—prostate cancer	1.51e-05	0.000128	CcSEcCtD
Eletriptan—Somnolence—Epirubicin—prostate cancer	1.51e-05	0.000128	CcSEcCtD
Eletriptan—Anorexia—Doxorubicin—prostate cancer	1.5e-05	0.000127	CcSEcCtD
Eletriptan—Nausea—Docetaxel—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Eletriptan—Dyspepsia—Epirubicin—prostate cancer	1.49e-05	0.000127	CcSEcCtD
Eletriptan—Diarrhoea—Prednisone—prostate cancer	1.48e-05	0.000126	CcSEcCtD
Eletriptan—Decreased appetite—Epirubicin—prostate cancer	1.47e-05	0.000125	CcSEcCtD
Eletriptan—Hypotension—Doxorubicin—prostate cancer	1.47e-05	0.000124	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Epirubicin—prostate cancer	1.46e-05	0.000124	CcSEcCtD
Eletriptan—Fatigue—Epirubicin—prostate cancer	1.46e-05	0.000124	CcSEcCtD
Eletriptan—Constipation—Epirubicin—prostate cancer	1.45e-05	0.000123	CcSEcCtD
Eletriptan—Pain—Epirubicin—prostate cancer	1.45e-05	0.000123	CcSEcCtD
Eletriptan—Nausea—Capecitabine—prostate cancer	1.45e-05	0.000123	CcSEcCtD
Eletriptan—Dizziness—Prednisone—prostate cancer	1.43e-05	0.000122	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.43e-05	0.000121	CcSEcCtD
Eletriptan—Insomnia—Doxorubicin—prostate cancer	1.42e-05	0.00012	CcSEcCtD
Eletriptan—Paraesthesia—Doxorubicin—prostate cancer	1.41e-05	0.00012	CcSEcCtD
Eletriptan—Dyspnoea—Doxorubicin—prostate cancer	1.4e-05	0.000119	CcSEcCtD
Eletriptan—Feeling abnormal—Epirubicin—prostate cancer	1.4e-05	0.000119	CcSEcCtD
Eletriptan—Somnolence—Doxorubicin—prostate cancer	1.39e-05	0.000118	CcSEcCtD
Eletriptan—Gastrointestinal pain—Epirubicin—prostate cancer	1.39e-05	0.000118	CcSEcCtD
Eletriptan—Dyspepsia—Doxorubicin—prostate cancer	1.38e-05	0.000117	CcSEcCtD
Eletriptan—Vomiting—Prednisone—prostate cancer	1.38e-05	0.000117	CcSEcCtD
Eletriptan—Rash—Prednisone—prostate cancer	1.37e-05	0.000116	CcSEcCtD
Eletriptan—Dermatitis—Prednisone—prostate cancer	1.37e-05	0.000116	CcSEcCtD
Eletriptan—Decreased appetite—Doxorubicin—prostate cancer	1.36e-05	0.000116	CcSEcCtD
Eletriptan—Headache—Prednisone—prostate cancer	1.36e-05	0.000115	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.35e-05	0.000115	CcSEcCtD
Eletriptan—Fatigue—Doxorubicin—prostate cancer	1.35e-05	0.000115	CcSEcCtD
Eletriptan—Urticaria—Epirubicin—prostate cancer	1.35e-05	0.000114	CcSEcCtD
Eletriptan—Pain—Doxorubicin—prostate cancer	1.34e-05	0.000114	CcSEcCtD
Eletriptan—Constipation—Doxorubicin—prostate cancer	1.34e-05	0.000114	CcSEcCtD
Eletriptan—Abdominal pain—Epirubicin—prostate cancer	1.34e-05	0.000114	CcSEcCtD
Eletriptan—Body temperature increased—Epirubicin—prostate cancer	1.34e-05	0.000114	CcSEcCtD
Eletriptan—Feeling abnormal—Doxorubicin—prostate cancer	1.29e-05	0.00011	CcSEcCtD
Eletriptan—Nausea—Prednisone—prostate cancer	1.29e-05	0.000109	CcSEcCtD
Eletriptan—Gastrointestinal pain—Doxorubicin—prostate cancer	1.28e-05	0.000109	CcSEcCtD
Eletriptan—Hypersensitivity—Epirubicin—prostate cancer	1.25e-05	0.000106	CcSEcCtD
Eletriptan—Urticaria—Doxorubicin—prostate cancer	1.25e-05	0.000106	CcSEcCtD
Eletriptan—Body temperature increased—Doxorubicin—prostate cancer	1.24e-05	0.000105	CcSEcCtD
Eletriptan—Abdominal pain—Doxorubicin—prostate cancer	1.24e-05	0.000105	CcSEcCtD
Eletriptan—Asthenia—Epirubicin—prostate cancer	1.22e-05	0.000103	CcSEcCtD
Eletriptan—Pruritus—Epirubicin—prostate cancer	1.2e-05	0.000102	CcSEcCtD
Eletriptan—Diarrhoea—Epirubicin—prostate cancer	1.16e-05	9.85e-05	CcSEcCtD
Eletriptan—Hypersensitivity—Doxorubicin—prostate cancer	1.16e-05	9.81e-05	CcSEcCtD
Eletriptan—Asthenia—Doxorubicin—prostate cancer	1.13e-05	9.56e-05	CcSEcCtD
Eletriptan—Dizziness—Epirubicin—prostate cancer	1.12e-05	9.52e-05	CcSEcCtD
Eletriptan—Pruritus—Doxorubicin—prostate cancer	1.11e-05	9.42e-05	CcSEcCtD
Eletriptan—Vomiting—Epirubicin—prostate cancer	1.08e-05	9.15e-05	CcSEcCtD
Eletriptan—Diarrhoea—Doxorubicin—prostate cancer	1.07e-05	9.11e-05	CcSEcCtD
Eletriptan—Rash—Epirubicin—prostate cancer	1.07e-05	9.08e-05	CcSEcCtD
Eletriptan—Dermatitis—Epirubicin—prostate cancer	1.07e-05	9.07e-05	CcSEcCtD
Eletriptan—Headache—Epirubicin—prostate cancer	1.06e-05	9.02e-05	CcSEcCtD
Eletriptan—Dizziness—Doxorubicin—prostate cancer	1.04e-05	8.81e-05	CcSEcCtD
Eletriptan—Nausea—Epirubicin—prostate cancer	1.01e-05	8.55e-05	CcSEcCtD
Eletriptan—Vomiting—Doxorubicin—prostate cancer	9.98e-06	8.47e-05	CcSEcCtD
Eletriptan—Rash—Doxorubicin—prostate cancer	9.89e-06	8.4e-05	CcSEcCtD
Eletriptan—Dermatitis—Doxorubicin—prostate cancer	9.88e-06	8.39e-05	CcSEcCtD
Eletriptan—Headache—Doxorubicin—prostate cancer	9.83e-06	8.35e-05	CcSEcCtD
Eletriptan—Nausea—Doxorubicin—prostate cancer	9.32e-06	7.91e-05	CcSEcCtD
Eletriptan—CYP2D6—Metabolism—COMT—prostate cancer	1.54e-06	2.31e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—prostate cancer	1.54e-06	2.31e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—prostate cancer	1.54e-06	2.3e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTP1—prostate cancer	1.54e-06	2.3e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTM1—prostate cancer	1.53e-06	2.3e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1A—prostate cancer	1.53e-06	2.3e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—COMT—prostate cancer	1.53e-06	2.29e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—prostate cancer	1.53e-06	2.29e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—prostate cancer	1.53e-06	2.29e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—prostate cancer	1.53e-06	2.29e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	1.53e-06	2.29e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTP1—prostate cancer	1.52e-06	2.28e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	1.52e-06	2.28e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—prostate cancer	1.52e-06	2.28e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1B—prostate cancer	1.52e-06	2.27e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—TYMS—prostate cancer	1.51e-06	2.27e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CB—prostate cancer	1.51e-06	2.27e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	1.51e-06	2.27e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ITPR1—prostate cancer	1.51e-06	2.27e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—LPL—prostate cancer	1.51e-06	2.26e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	1.5e-06	2.25e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—prostate cancer	1.5e-06	2.25e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—prostate cancer	1.5e-06	2.25e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ITPR1—prostate cancer	1.5e-06	2.25e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTM1—prostate cancer	1.5e-06	2.24e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—prostate cancer	1.5e-06	2.24e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HPGDS—prostate cancer	1.49e-06	2.24e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—prostate cancer	1.49e-06	2.24e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	1.49e-06	2.23e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.49e-06	2.23e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	1.49e-06	2.23e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—prostate cancer	1.49e-06	2.23e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CASP3—prostate cancer	1.49e-06	2.23e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—prostate cancer	1.48e-06	2.23e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.48e-06	2.22e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—prostate cancer	1.48e-06	2.22e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—prostate cancer	1.48e-06	2.22e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—prostate cancer	1.48e-06	2.21e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.47e-06	2.21e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—prostate cancer	1.47e-06	2.21e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—LPL—prostate cancer	1.47e-06	2.2e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EP300—prostate cancer	1.46e-06	2.19e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CYP1A1—prostate cancer	1.45e-06	2.18e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—prostate cancer	1.45e-06	2.17e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTT1—prostate cancer	1.45e-06	2.17e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ACHE—prostate cancer	1.45e-06	2.17e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EP300—prostate cancer	1.45e-06	2.17e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—prostate cancer	1.45e-06	2.17e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ERCC2—prostate cancer	1.44e-06	2.16e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—FGF2—prostate cancer	1.44e-06	2.16e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CTNNB1—prostate cancer	1.43e-06	2.15e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CB—prostate cancer	1.43e-06	2.15e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.43e-06	2.15e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TYMS—prostate cancer	1.43e-06	2.14e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NOS3—prostate cancer	1.42e-06	2.13e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP1A1—prostate cancer	1.42e-06	2.13e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—prostate cancer	1.42e-06	2.13e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EP300—prostate cancer	1.42e-06	2.13e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SRC—prostate cancer	1.42e-06	2.12e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TYMS—prostate cancer	1.42e-06	2.12e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTM1—prostate cancer	1.41e-06	2.12e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SRC—prostate cancer	1.41e-06	2.11e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ERCC2—prostate cancer	1.41e-06	2.11e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—prostate cancer	1.4e-06	2.11e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1A—prostate cancer	1.4e-06	2.1e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—prostate cancer	1.4e-06	2.1e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTM1—prostate cancer	1.4e-06	2.1e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—prostate cancer	1.4e-06	2.09e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.39e-06	2.09e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PRKACB—prostate cancer	1.39e-06	2.08e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—LPL—prostate cancer	1.38e-06	2.08e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—prostate cancer	1.38e-06	2.07e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—JAK2—prostate cancer	1.38e-06	2.07e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SRC—prostate cancer	1.38e-06	2.07e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—LPL—prostate cancer	1.37e-06	2.06e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—prostate cancer	1.37e-06	2.06e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.37e-06	2.06e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—prostate cancer	1.37e-06	2.05e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—prostate cancer	1.37e-06	2.05e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—prostate cancer	1.36e-06	2.04e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—prostate cancer	1.36e-06	2.04e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—MTHFR—prostate cancer	1.36e-06	2.03e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	1.35e-06	2.03e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MDM2—prostate cancer	1.35e-06	2.02e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—prostate cancer	1.34e-06	2.01e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.34e-06	2.01e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EP300—prostate cancer	1.33e-06	2e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARA—prostate cancer	1.33e-06	1.99e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—prostate cancer	1.33e-06	1.99e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ERBB2—prostate cancer	1.33e-06	1.99e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ERCC2—prostate cancer	1.33e-06	1.99e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.33e-06	1.99e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—MTHFR—prostate cancer	1.32e-06	1.98e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ERCC2—prostate cancer	1.32e-06	1.97e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	1.31e-06	1.97e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—prostate cancer	1.31e-06	1.96e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NCOA2—prostate cancer	1.31e-06	1.96e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARA—prostate cancer	1.3e-06	1.95e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SRC—prostate cancer	1.3e-06	1.94e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—prostate cancer	1.29e-06	1.94e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—prostate cancer	1.27e-06	1.9e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TGFB1—prostate cancer	1.27e-06	1.9e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—prostate cancer	1.26e-06	1.89e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—prostate cancer	1.26e-06	1.89e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—prostate cancer	1.26e-06	1.89e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TGFB1—prostate cancer	1.26e-06	1.89e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CAV1—prostate cancer	1.25e-06	1.87e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—prostate cancer	1.25e-06	1.87e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—EP300—prostate cancer	1.25e-06	1.87e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—MTHFR—prostate cancer	1.25e-06	1.87e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.25e-06	1.87e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—prostate cancer	1.24e-06	1.86e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—prostate cancer	1.24e-06	1.85e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—MTHFR—prostate cancer	1.24e-06	1.85e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—prostate cancer	1.24e-06	1.85e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—prostate cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TGFB1—prostate cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	1.23e-06	1.84e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARA—prostate cancer	1.22e-06	1.83e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CAV1—prostate cancer	1.22e-06	1.83e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.22e-06	1.82e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	1.22e-06	1.82e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARA—prostate cancer	1.21e-06	1.82e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—prostate cancer	1.21e-06	1.81e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CASP3—prostate cancer	1.21e-06	1.81e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—prostate cancer	1.2e-06	1.8e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NQO1—prostate cancer	1.2e-06	1.8e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—prostate cancer	1.2e-06	1.8e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.19e-06	1.79e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TH—prostate cancer	1.19e-06	1.78e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—EP300—prostate cancer	1.18e-06	1.77e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—prostate cancer	1.17e-06	1.76e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—prostate cancer	1.17e-06	1.76e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—prostate cancer	1.17e-06	1.75e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	1.16e-06	1.74e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—prostate cancer	1.16e-06	1.74e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TGFB1—prostate cancer	1.16e-06	1.74e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.15e-06	1.73e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CAV1—prostate cancer	1.15e-06	1.72e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—prostate cancer	1.14e-06	1.71e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CAV1—prostate cancer	1.14e-06	1.71e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—prostate cancer	1.14e-06	1.71e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.14e-06	1.71e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—prostate cancer	1.14e-06	1.7e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	1.14e-06	1.7e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—prostate cancer	1.13e-06	1.7e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GGT1—prostate cancer	1.12e-06	1.68e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—prostate cancer	1.11e-06	1.67e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—prostate cancer	1.1e-06	1.66e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NCOA1—prostate cancer	1.1e-06	1.65e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.09e-06	1.63e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.08e-06	1.63e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EP300—prostate cancer	1.08e-06	1.62e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—INS—prostate cancer	1.08e-06	1.62e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—prostate cancer	1.08e-06	1.62e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—prostate cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CREBBP—prostate cancer	1.06e-06	1.58e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—INS—prostate cancer	1.05e-06	1.58e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SRC—prostate cancer	1.05e-06	1.57e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	1.05e-06	1.57e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.05e-06	1.57e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—RXRA—prostate cancer	1.05e-06	1.57e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—prostate cancer	1.04e-06	1.56e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.04e-06	1.56e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—prostate cancer	1.04e-06	1.55e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CREBBP—prostate cancer	1.03e-06	1.55e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—prostate cancer	1.02e-06	1.53e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—prostate cancer	1.01e-06	1.52e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—prostate cancer	1.01e-06	1.52e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—COMT—prostate cancer	1.01e-06	1.51e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTP1—prostate cancer	1e-06	1.51e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CD—prostate cancer	1e-06	1.5e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—INS—prostate cancer	9.92e-07	1.49e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ITPR1—prostate cancer	9.88e-07	1.48e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	9.85e-07	1.48e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—INS—prostate cancer	9.83e-07	1.47e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CD—prostate cancer	9.77e-07	1.47e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CREBBP—prostate cancer	9.71e-07	1.46e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CREBBP—prostate cancer	9.63e-07	1.44e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—prostate cancer	9.55e-07	1.43e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—prostate cancer	9.53e-07	1.43e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—prostate cancer	9.49e-07	1.42e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NOS3—prostate cancer	9.46e-07	1.42e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—prostate cancer	9.41e-07	1.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TGFB1—prostate cancer	9.39e-07	1.41e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMS—prostate cancer	9.33e-07	1.4e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—prostate cancer	9.29e-07	1.39e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NOS3—prostate cancer	9.23e-07	1.38e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—prostate cancer	9.23e-07	1.38e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTM1—prostate cancer	9.22e-07	1.38e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CD—prostate cancer	9.21e-07	1.38e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—prostate cancer	9.21e-07	1.38e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CD—prostate cancer	9.13e-07	1.37e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—LPL—prostate cancer	9.05e-07	1.36e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—prostate cancer	8.81e-07	1.32e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—prostate cancer	8.75e-07	1.31e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP1A1—prostate cancer	8.74e-07	1.31e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CB—prostate cancer	8.73e-07	1.31e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—prostate cancer	8.73e-07	1.31e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—prostate cancer	8.72e-07	1.31e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NOS3—prostate cancer	8.7e-07	1.3e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—prostate cancer	8.7e-07	1.3e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ERCC2—prostate cancer	8.67e-07	1.3e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—prostate cancer	8.65e-07	1.3e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NOS3—prostate cancer	8.62e-07	1.29e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—prostate cancer	8.57e-07	1.28e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CB—prostate cancer	8.52e-07	1.28e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—prostate cancer	8.44e-07	1.27e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—MTHFR—prostate cancer	8.15e-07	1.22e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—prostate cancer	8.05e-07	1.21e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CB—prostate cancer	8.03e-07	1.2e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARA—prostate cancer	8e-07	1.2e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	7.99e-07	1.2e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CB—prostate cancer	7.96e-07	1.19e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—prostate cancer	7.95e-07	1.19e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—prostate cancer	7.89e-07	1.18e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—prostate cancer	7.73e-07	1.16e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—prostate cancer	7.54e-07	1.13e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—prostate cancer	7.54e-07	1.13e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CAV1—prostate cancer	7.52e-07	1.13e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—prostate cancer	7.36e-07	1.1e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—EP300—prostate cancer	7.19e-07	1.08e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—prostate cancer	7.13e-07	1.07e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—prostate cancer	7.08e-07	1.06e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—EP300—prostate cancer	7.02e-07	1.05e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—prostate cancer	6.94e-07	1.04e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—prostate cancer	6.88e-07	1.03e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—prostate cancer	6.85e-07	1.03e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—EP300—prostate cancer	6.62e-07	9.92e-06	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—EP300—prostate cancer	6.56e-07	9.83e-06	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—prostate cancer	6.53e-07	9.79e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—INS—prostate cancer	6.48e-07	9.72e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CREBBP—prostate cancer	6.35e-07	9.52e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.02e-07	9.03e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NOS3—prostate cancer	5.69e-07	8.52e-06	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—prostate cancer	5.32e-07	7.98e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.25e-07	7.87e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—prostate cancer	5.2e-07	7.8e-06	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—prostate cancer	5.19e-07	7.79e-06	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.89e-07	7.34e-06	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—prostate cancer	4.85e-07	7.27e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—prostate cancer	4.54e-07	6.8e-06	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—prostate cancer	4.35e-07	6.52e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—EP300—prostate cancer	4.33e-07	6.48e-06	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—prostate cancer	4.24e-07	6.36e-06	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—prostate cancer	4e-07	5.99e-06	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—prostate cancer	3.96e-07	5.94e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.2e-07	4.8e-06	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—prostate cancer	2.61e-07	3.92e-06	CbGpPWpGaD
